Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
|Patrick Van Dreden, Loula Papageorgiou, Despina Fotiou, Gueye Mor Seny, Laurent Garderet, Evagelos Terpos, Stella Salta, Theodoros Sergentanis, Athanasios Dimopoulos, Annette K Larsen, Ismail Elalamy and Grigoris T Gerotziafas,|
|Diagnostica Stago, AsniÃ¨res-sur-Seine, France
University of Athens, Greece
HÃ´pital Saint-Antoine, France
HÃ´pital Tenon (AP-HP), France
Centre de Recherche Saint Antoine - INSERM, France
|Posters & Accepted Abstracts: J Blood Disord Transfus|
|Background: Multiple myeloma (MM) and the associated immunomodulatory (IMiD) treatments are associated with
risk of vascular complications. Thrombin generation (TG) assessment reflects the equilibrium between procoagulant and
anticoagulant activities in the plasma.
Aim: We conducted a multicenter study to explore the relationship between stages of MM and alterations of thrombin
Methods: Patients with MM (n=129) were recruited from July 2014 to December 2016 and stratified to the following groups:
44 newly diagnosed treatment-naÃ¯ve patients (ND), 33 patients receiving IMiDs (IM), 45 in complete remission (CR) and 7
patients in partial remission on IMiDs (PR/IM). Patients on anticoagulant treatment were excluded from the study. The control
group (CG) consisted of 30 healthy age and sex-matched individuals. Samples of platelet-poor plasma (PPP) were assessed for
thrombin generation (TG) with the TF 5pM PPP-ReagentÂ® on Calibrated Automated Thrombogram (Stago, France). The upper
and lower normal limits (LNL and UNL) were calculated by the meanÂ±2 SD.
Results: Patients with ongoing MM (ND, IM, PR/IM) had significantly lower peak, ETP and MRI as compared to the CG.
In contrast, patients in CR had peak, ETP, MRI values similar to the CG. Patients with PR had lower ETP and MRI values as
compared to the CR group (Table 1). In ND 8% had TG>UNL and 20% had TG|
Patrick Van Dreden is a Head of Clinical Research Department and Prospective Research Manager at Diagnostics Stago. He has Degree of Hemostasis study: Pathogenesis and pharmacology of thrombosis. He is an International Member of Society of Haemostasis and Thrombosis, Member of the European Thrombosis Research Organization, Member of the Mediterranean League against Thromboembolic Diseases, Member of the American Society of Hematology and Member of International Academy of Clinical and Applied Thrombosis/Hemostasis.
|PDF | HTML|